Is GE Healthcare Technologies, Inc. overvalued or undervalued?

As of 14 November 2025, the valuation grade for GE Healthcare Technologies, Inc. moved from very attractive to attractive. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 14, an EV to EBITDA of 11.16, and a PEG ratio of 0.39, which suggest that the stock is reasonably priced relative to its earnings growth potential.
In comparison to peers, GE Healthcare's P/E ratio of 14 is significantly lower than Edwards Lifesciences Corp.'s P/E of 31.17 and Agilent Technologies, Inc.'s P/E of 27.42, indicating a more attractive valuation relative to these companies. Additionally, while GE Healthcare has underperformed against the S&P 500 with a year-to-date return of -9.66% compared to the index's 14.49%, this may present a buying opportunity for investors looking for value in the pharmaceuticals and biotechnology sector.